Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy

被引:0
|
作者
De Lucia, Anna [1 ]
Mazzotti, Lucia [1 ,2 ]
Gaimari, Anna [1 ,2 ]
Zurlo, Matteo [1 ]
Maltoni, Roberta [3 ]
Cerchione, Claudio [4 ]
Bravaccini, Sara [5 ]
Delmonte, Angelo [6 ]
Crino, Lucio [6 ]
de Souza, Patricia Borges [1 ]
Pasini, Luigi [1 ,10 ]
Nicolini, Fabio [1 ]
Bianchi, Fabrizio [7 ]
Juan, Manel [8 ]
Calderon, Hugo [8 ]
Magnoni, Chiara [1 ,2 ]
Gazzola, Luca [1 ,2 ]
Ulivi, Paola [9 ]
Mazza, Massimiliano [1 ]
机构
[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Adv Cellular Therapies & Rare Tumors Unit, Meldola, Italy
[2] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy
[3] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Healthcare Adm, Meldola, Italy
[4] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Hematol Unit, Meldola, Italy
[5] Kore Univ Enna, Dept Med & Surg, Enna, Italy
[6] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Med Oncol Dept, Meldola, Italy
[7] Fdn IRCCS Casa Sollievo Sofferenza, Unit Canc Biomarker, San Giovanni Rotondo, FG, Italy
[8] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Dept Immunol, Barcelona, Spain
[9] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Translat Oncol Unit, Meldola, Italy
[10] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Meldola, FC, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
关键词
non-small cell lung cancer (NSCLC); tumor microenvironment (TME); tyrosine kinase inhibitors (TKIs); immune checkpoint inhibitors (ICIs); chimeric antigen receptor (CAR) T cell therapy; CHIMERIC ANTIGEN RECEPTOR; CAR-T-CELLS; TERTIARY LYMPHOID STRUCTURES; GROWTH-FACTOR RECEPTOR; OPEN-LABEL; EGFR-MUTATION; 1ST-LINE TREATMENT; ACQUIRED-RESISTANCE; IMMUNE CELLS; SOLID TUMORS;
D O I
10.3389/fimmu.2025.1515748
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past decades, significant progress has been made in the understanding of non-small cell lung cancer (NSCLC) biology and tumor progression mechanisms, resulting in the development of novel strategies for early detection and wide-ranging care approaches. Since their introduction, over 20 years ago, targeted therapies with tyrosine kinase inhibitors (TKIs) have revolutionized the treatment landscape for NSCLC. Nowadays, targeted therapies remain the gold standard for many patients, but still they suffer from many adverse effects, including unexpected toxicity and intrinsic acquired resistance mutations, which lead to relapse. The adoption of immune checkpoint inhibitors (ICIs) in 2015, has offered exceptional survival benefits for patients without targetable alterations. Despite this notable progress, challenges remain, as not all patients respond favorably to ICIs, and resistance to therapy can develop over time. A crucial factor influencing clinical response to immunotherapy is the tumor microenvironment (TME). The TME is pivotal in orchestrating the interactions between neoplastic cells and the immune system, influencing tumor growth and treatment outcomes. In this review, we discuss how the understanding of this intricate relationship is crucial for the success of immunotherapy and survey the current state of immunotherapy intervention, with a focus on forthcoming and promising chimeric antigen receptor (CAR) T cell therapies in NSCLC. The TME sets major obstacles for CAR-T therapies, creating conditions that suppress the immune response, inducing T cell exhaustion. To enhance treatment efficacy, specific efforts associated with CAR-T cell therapy in NSCLC, should definitely focus TME-related immunosuppression and antigen escape mechanisms, by combining CAR-T cells with immune checkpoint blockades.
引用
收藏
页数:21
相关论文
共 50 条
  • [41] Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer
    Rivera-Concepcion, Joel
    Uprety, Dipesh
    Adjei, Alex A.
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 315 - 329
  • [42] Targeted therapies and radiation therapy in non-small cell lung cancer
    Rivera, S.
    Quero, L.
    Kam, S. Wong Hee
    Maylin, C.
    Deutsch, E.
    Hennequin, C.
    CANCER RADIOTHERAPIE, 2011, 15 (6-7): : 527 - 535
  • [43] How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?
    Linda E. Coate
    Natasha B. Leighl
    Current Treatment Options in Oncology, 2011, 12 : 1 - 11
  • [44] Targeted/Emerging Therapies for Metastatic Non-Small Cell Lung Cancer
    Horn, Leora
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 676 - 678
  • [45] How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?
    Coate, Linda E.
    Leighl, Natasha B.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2011, 12 (01) : 1 - 11
  • [46] Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
    Halliday, Patrick R.
    Blakely, Collin M.
    Bivona, Trever G.
    CURRENT ONCOLOGY REPORTS, 2019, 21 (03)
  • [47] MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview
    Tibaldi, Carmelo
    D'Incecco, Armida
    Lagana, Alessandro
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2015, 15 (06) : 694 - 700
  • [48] Targeted Therapies for Non-Small Cell Lung Cancer: An Evolving Landscape
    Pal, Sumanta Kumar
    Figlin, Robert A.
    Reckamp, Karen
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (07) : 1931 - 1944
  • [49] New Targeted Therapies for Metastatic Non-Small Cell Lung Cancer
    Riely, Gregory J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22
  • [50] Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer
    Shroff, Girish S.
    de Groot, Patricia M.
    Papadimitrakopoulou, Vassiliki A.
    Truong, Mylene T.
    Carter, Brett W.
    RADIOLOGIC CLINICS OF NORTH AMERICA, 2018, 56 (03) : 485 - +